Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | DGAT1 | O75907 | 3/20 | 0.32 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.31 |
| ▸ | FEN1 | P39748 | 2/20 | 0.31 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3389626 | 0.83 | DGAT1 (0.32) | NPC1DGAT1 | |
| SCHEMBL15880359 | 0.81 | ALDH1A1 (0.40) | ALDH1A1TDP1MEN1KMT2AL3MBTL1 | |
| SCHEMBL3496820 | 0.81 | DGAT1 (0.35) | L3MBTL1NPC1DGAT1PDE10A | |
| SCHEMBL3017173 | 0.80 | KEAP1 (0.49) | ALDH1A1MEN1KMT2AL3MBTL1NPC1 | |
| SCHEMBL31308722 | 0.80 | DGAT1 (0.35) | NPC1DGAT1ALOX5APFEN1 | |
| SCHEMBL30789772 | 0.80 | DGAT1 (0.33) | NPC1DGAT1 | |
| SCHEMBL20744490 | 0.80 | DGAT1 (0.40) | NPC1DGAT1 | |
| SCHEMBL15881388 | 0.79 | ALDH1A1 (0.42) | ALDH1A1TDP1MEN1KMT2AL3MBTL1 | |
| SCHEMBL5246866 | 0.79 | NPC1 (0.33) | NPC1DGAT1 | |
| SCHEMBL22546426 | 0.79 | ALDH1A1 (0.38) | ALDH1A1TDP1MEN1KMT2AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 137 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260070896-A1 | HETEROCYCLE DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS | UNIV LEUVEN KATH (BE) | 2026-03-12 | — | — | US | disclosed |
| EP-4683918-A1 | NLRP3 INFLAMMASOME INHIBITORS AND USES THEREOF | Insilico Medicine IP Limited (HK) | 2026-01-28 | — | — | EP | disclosed |
| US-12404266-B2 | Heterocycle derivatives for treating TRPM3 mediated disorders | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2025-09-02 | — | — | US | disclosed |
| US-12209081-B2 | Heterocycle derivatives for treating TRPM3 mediated disorders | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2025-01-28 | — | — | US | disclosed |
| US-20240360085-A1 | Glucose Uptake Inhibitors | KADMON CORPORATION, LLC (US) | 2024-10-31 | — | — | US | disclosed |
| US-20240336602-A1 | HETEROCYCLE DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS | UNIV LEUVEN KATH (BE) | 2024-10-10 | — | — | US | disclosed |
| WO-2024193541-A1 | NLRP3 INFLAMMASOME INHIBITORS AND USES THEREOF | INSILICO MEDICINE IP LIMITED (CN) | 2024-09-26 | — | — | WO | disclosed |
| CN-113614095-B | Alkylboronic acids as arginase inhibitors | 广东新契生物医药科技有限公司 | 2024-08-23 | — | — | CN | disclosed |
| US-12030857-B2 | Glucose uptake inhibitors | KADMON CORPORATION, LLC (US) | 2024-07-09 | — | — | US | disclosed |
| US-12030857-B2 | Glucose uptake inhibitors | KADMON CORPORATION, LLC (US) | 2024-07-09 | — | — | US | disclosed |
| EP-2017279-A1 | NOVEL AMINOPYRIDINE DERIVATIVE HAVING AURORA-A-SELECTIVE INHIBITORY ACTIVITY | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-01-21 | — | — | EP | disclosed |
| US-20080058347-A1 | Novel aminopyridine derivatives having aurora a selective inhibitory action | MSD K.K. (JP) | 2008-03-06 | — | — | US | disclosed |
| US-20080027042-A1 | Novel Aminopyridine Derivatives Having Aurora a Selective Inhibitory Action | OHKUBO MITSURU | 2008-01-31 | — | — | US | disclosed |
| US-20080027042-A1 | Novel Aminopyridine Derivatives Having Aurora a Selective Inhibitory Action | OHKUBO MITSURU | 2008-01-31 | — | — | US | disclosed |
| US-20080027042-A1 | Novel Aminopyridine Derivatives Having Aurora a Selective Inhibitory Action | OHKUBO MITSURU | 2008-01-31 | — | — | US | disclosed |
| EP-1828165-A1 | NOVEL AMINOPYRIDINE DERIVATIVES HAVING AURORA A SELECTIVE INHIBITORY ACTION | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-09-05 | — | — | EP | disclosed |
| EP-1813609-A2 | NOVEL AMINOPYRIDINE DERIVATIVES HAVING SELECTIVE AURORA-A INHIBITORY EFFECT | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-08-01 | — | — | EP | disclosed |
| EP-1813609-A2 | NOVEL AMINOPYRIDINE DERIVATIVES HAVING SELECTIVE AURORA-A INHIBITORY EFFECT | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-08-01 | — | — | EP | disclosed |
| US-20060106029-A1 | Novel aminopyridine derivatives having aurora a selective inhibitory action | MSD K.K. (JP) | 2006-05-18 | — | — | US | disclosed |
| WO-2006046735-A1 | NOVEL AMINOPYRIDINE DERIVATIVES HAVING AURORA A SELECTIVE INHIBITORY ACTION | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12209081-B2 | Heterocycle derivatives for treating TRPM3 mediated disorders | TRPM4, TRPM6, TRPM2 | ALDH1A1 2383/4885TDP1 3449/4885MEN1 1036/4885 |
| US-12030857-B2 | Glucose uptake inhibitors | SLC2A1, SLC2A4, SLC2A2 | ALDH1A1 1422/4885TDP1 3804/4885MEN1 1114/4885 |
| US-20080027042-A1 | Novel Aminopyridine Derivatives Having Aurora a Selective Inhibitory Action | AURKA, AURKC, AURKB | ALDH1A1 1644/4885TDP1 746/4885MEN1 671/4885 |
| US-20080058347-A1 | Novel aminopyridine derivatives having aurora a selective inhibitory action | AURKA, AURKC, AURKB | ALDH1A1 3251/4885TDP1 775/4885MEN1 1321/4885 |
| US-20060106029-A1 | Novel aminopyridine derivatives having aurora a selective inhibitory action | AURKA, AURKC, AURKB | ALDH1A1 1644/4885TDP1 746/4885MEN1 671/4885 |
| US-12404266-B2 | Heterocycle derivatives for treating TRPM3 mediated disorders | TRPM4, TRPM6, TRPM2 | ALDH1A1 2383/4885TDP1 3449/4885MEN1 1036/4885 |
| US-20240360085-A1 | Glucose Uptake Inhibitors | SLC2A3, SLC2A1, SLC2A4 | ALDH1A1 1565/4885TDP1 3799/4885MEN1 1011/4885 |
| US-20260070896-A1 | HETEROCYCLE DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS | TRPM6, TRPV3, TRPM2 | ALDH1A1 3564/4885TDP1 4296/4885MEN1 3849/4885 |
| US-20240336602-A1 | HETEROCYCLE DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS | TRPM4, TRPM6, TRPM2 | ALDH1A1 2383/4885TDP1 3449/4885MEN1 1036/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.